Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WILMA: Could you provide me with the links for both articles.....You can't.... I thought so!!
WILMA: Since when the statement "taking a company public" means that's an IPO. I think we have a failure to understand THE DIFFERENCE here!!
WILMA: You ain't going to scare anyone here into selling you cheap shares. You already had you chance to pick up share on the cheap and you blew it.
Myself and others who are die hard holders of KEYO stock are intrigued by others who don't own keyo but promote negativity on the stock at every opportunity.
#6 on the Breakout boards!!!!!Houston...We are about to lift off...10..9..8..7
An older report from the WSJ:
And while he stopped short of saying that his new company–Los Angeles-based Nantworks LLC–will definitely file to go public, he said he expects the company to become a powerful standalone player in the high-tech health system that the country is moving toward. He talked to Venture Capital Dispatch about the complex picture for new biotech issues on the public market
Dr. Soon never divulge any information regarding if and how he is going to take NANTWORKS LLC to the market.
http://blogs.wsj.com/venturecapital/2014/06/26/doctor-founder-billionaire-talks-about-biotech-investment-stocks/
IP man excellent find. This article is in line with the good "DOC" philosophy. It's just a waiting game now.
Dr.Patrick Soon-Shiong paid Celgene $135 million for NantWorks, where he had begun the work of creating his planned high-tech health delivery network.
He contacted potential partners for the venture, including meeting AEG owner Anschutz, with whom he spent a day in the Denver suburb of Aurora touring the Anshutz Medical Campus.
Soon-Shiong also bought or provided seed money to small technology companies to aid in that effort.
He paid $20 million to buy a controlling interest in KeyOn Communications.
http://www.reuters.com/article/2012/10/03/us-soon-shiong-idUSBRE89205320121003
Check out the last paragraph of this article. "Billionaire doctor wants to install a genome-analyzing supercomputer at a children’s hospital."
https://gigaom.com/2014/10/07/billionaire-doctor-wants-to-install-a-genome-analyzing-supercomputer-at-a-childrens-hospital/
RDY2ROCK:AMEN....WELL SAID!KEEP ON ROCKING...
Billionaire Soon-Shiong partners with PCH on genomics super computer:
http://www.bizjournals.com/phoenix/blog/health-care-daily/2014/10/billionaire-soon-shiong-partners-with-pch-on.html
Not so quick. Ever heard of Mapp Biopharmaceutical Inc. Check this out:
http://www.bloomberg.com/news/2014-08-05/ebola-drug-made-from-tobacco-plant-saves-u-s-aid-workers.html
--
Dr. Patrick Soon-Shiong among the top 40 wealthiest Americans ($11.9 Billion):
http://www.catholic.org/news/business/story.php?id=57099
If Dr.Soon-Shiong teams up with Jeff Hawkins this could solve our Data problems.
https://gigaom.com/2014/09/24/the-gigaom-interview-jeff-hawkins-on-why-his-approach-to-ai-will-become-the-approach-to-ai/
Blackstone invested in Nantworks:
07/24/2012
Blackstone Invests $125 Million in Nantpharma, A Nantworks Company
Company will become premier provider of bio-derived products and critically needed injectables of the highest quality
Los Angeles, CA, and New York, NY, July 24, 2012 – California-based NantWorks, LLC, announced today that a fund managed by Blackstone (NYSE: BX) has invested US$125 million in NantPharma, a NantWorks company whose products include high quality, biologically derived pharmaceuticals. NantPharma operates a number of drug manufacturing and research facilities around the country. In January 2012, it announced the acquisition and redevelopment of a former Pfizer facility in Terre Haute, Indiana, with a commitment to invest $85.5 million to produce critical care injectable and oncological drugs. The new plant is expected to become operational in 2015.
NantWorks and NantPharma Chairman, Dr. Patrick Soon-Shiong, has previously founded two successful pharmaceutical companies addressing the unmet needs of critically ill patients. The injectable drug company he led, APP Pharmaceuticals, was the nation’s only safe source of heparin during the supply crisis in 2008, and his biopharmaceutical company, Abraxis Bioscience, developed the world’s first protein nanotechnology cancer drug transporter for breast cancer and now is in trials for pancreatic and lung cancer. Dr. Soon-Shiong sold these companies in 2008 and 2010, respectively, raising several billion dollars to pursue his vision of personalized medicine.
As part of the deal, Chinh E. Chu and Anjan Mukherjee, Blackstone Senior Managing Directors, and Arthur J. Higgins from Blackstone’s dedicated healthcare group, Blackstone Healthcare Partners, will join Dr. Patrick Soon-Shiong on the NantPharma board. Mr. Higgins is a former Chairman of the Board of Management of Bayer HealthCare AG, who led that company’s restructuring, including the acquisition of Schering AG and the over-the-counter medicines business of Roche. He is a former head of Abbott Laboratories’ pharmaceutical business in the United States, and a 34 year veteran of the pharmaceutical business.
“I am delighted that we will be building this company together with Blackstone and with seasoned executives Chinh Chu, Anjan Mukherjee and Art Higgins,” said Dr. Soon-Shiong, welcoming the agreement. “Our country must have absolutely reliable sources of blood plasma products. The effective treatment for auto immune and other diseases will depend on this. We must have the highest quality standards for all biologically derived drugs. Safety is paramount with such products.”
“We must also enhance our capabilities to manufacture injectable and next generation drugs in America,” added Dr. Soon-Shiong, noting that since 2010 there has been a growing and alarming shortage of injectable drugs for cancer sufferers and other critically ill patients.
Chinh Chu and Anjan Mukherjee, who have led many of Blackstone’s investments in healthcare, welcomed the agreement with NantPharma: “We have followed Dr. Soon-Shiong’s extraordinary career with much interest for nearly a decade and we see great opportunity working together with him at the leading edge of the healthcare industry, both in this exciting venture and other initiatives.”
Bank of America Merrill Lynch acted as financial advisor, and Fried, Frank, Harris, Shriver & Jacobson LLP served as legal counsel, to NantPharma and NantWorks in the transaction. Simpson Thacher & Bartlett served as legal counsel to Blackstone.
About NantWorks
NantWorks, LLC, is a company founded and led by Dr. Patrick Soon-Shiong. Its core mission is to converge a wide range of technologies to transform scientific discoveries, research and healthcare. It is building an integrated evidence-based, genomically-informed, personalized approach to the delivery of care and the development of next generation diagnostics and therapeutics. NantPharma is a NantWorks company specializing in pharmaceutical development and manufacturing. For more information, see www.nantworks.com.
About Blackstone
Blackstone (NYSE: BX) is one of the world's leading investment and advisory firms. Blackstone seeks to create positive economic impact and long-term value for its investors, the companies they invest in, the companies they advise and the broader global economy. Blackstone does this through the commitment of their extraordinary people and flexible capital. Their alternative asset management businesses include the management of private equity funds, real estate funds, hedge fund solutions, credit-oriented funds and closed-end mutual funds. Blackstone also provides various financial advisory services, including financial and strategic advisory, restructuring and reorganization advisory and fund placement services. Further information is available at www.blackstone.com.
###
Media Contact:
NantWorks
Jen Hodson
310.405.7539
jhodson@nantworks.com
Blackstone
Peter Rose
212.583.5871
rose@blackstone.com
September 15, 2014 01:31 PM Eastern Daylight Time
CORRECTION...by NantBioScience
LOS ANGELES--(BUSINESS WIRE)--Eighth paragraph, attribution should read: Patrick Soon-Shiong, M.D., CEO of NantBioScience (instead of Patrick Soon-Shiong, M.D., CEO of NantOmics).
“We are excited to partner with NantBioScience to one day bring our basic research of Ral protein inhibitors to the bedside of patients in the form of a new cancer fighting treatment”
The corrected release reads:
NANTBIOSCIENCE AND UNIVERSITY OF COLORADO TO COLLABORATE ON DEVELOPMENT OF NOVEL PROTEIN CANCER FIGHTING DRUGS
Partnership will focus on the Ral protein, an unexplored therapeutic target found to play a role in the growth and spread of cancer
NantBioScience, a NantWorks company focused on the discovery and development of innovative treatments for diseases with high unmet medical need, announced today a research collaboration and an exclusive worldwide licensing agreement with the University of Colorado for the development and commercialization of anti-cancer agents designed to target the Ral protein, a cell signaling protein implicated in the growth and spread of cancer. Through this partnership, NantBioScience will receive the exclusive right to develop and commercialize therapeutic and diagnostic products relating to the research activities.
NantBioScience’s broad development program includes novel agents that are designed to stop growth and spread of tumors by interfering with cancer communication pathways. Although the Ral protein has been found to play a role in the most commonly activated signaling pathways across cancer types, including colon, lung and pancreatic cancers, it has not yet been successfully targeted for potential therapeutic intervention. NantBioScience’s partnership with the University of Colorado and the Comprehensive Cancer Center is focused on the development of clinical compounds designed to block the function of the Ral protein.
“NantBioScience is committed to the discovery and development of cancer fighting therapies that target the key drivers and root causes of tumor growth and spread. Targeting the Ral protein expands our ongoing efforts to silence a key pathway, the RAS pathway, that has been found to be altered and constitutively activated in one out of three cancers,” said Shahrooz Rabizadeh, Ph.D., Chief Scientific Officer of NantBioScience. “We are pleased to be partnering with the University of Colorado, leaders in the science of inhibiting Ral function, to accelerate the development of novel cancer medicines for patients.”
Through structural and computational analysis, compounds that block the activity of Ral were identified by Dr. Dan Theodorescu and colleagues demonstrating the feasibility of developing potential treatments for this target. The results were published on September 14 in the journal Nature.
This pursuit of a clinical product targeting Ral is a collaborative effort, with teams from both the Univ. of Colorado and NantBioScience conducting research activities together.
“We are excited to partner with NantBioScience to one day bring our basic research of Ral protein inhibitors to the bedside of patients in the form of a new cancer fighting treatment,” said Dan Theodorescu, M.D., Ph.D., director of the University of Colorado Comprehensive Cancer Center.
NantBioScience’s portfolio includes clinical compounds designed to target changes at the molecular level based on the genomic and proteomic profile of the tumor, nano albumin-bound (nab®)-based molecules, novel remediators of p53 function, mutant K-Ras inhibitors, and potent multi-kinase inhibitors.
“This collaboration with Dr. Dan Theodorescu and the University of Colorado Comprehensive Cancer Center furthers our goal to catalyze personalized precision cancer care in our war against cancer," said Patrick Soon-Shiong, M.D., CEO of NantBioScience.
About NantBioScience
NantBioScience, a NantWorks company, is a biopharmaceutical company focused on the discovery of medicines designed to target the root cause of cancer growth and spread. Dr. Patrick Soon-Shiong, the creator of Abraxane® and the founder of the nano albumin-bound (nab®) technology platform, established NantBioScience in 2011. With a pipeline of nab®-based molecules and inhibitors of proteins that drive tumor growth, NantBioScience’s mission is to develop medicines designed to treat patients based on the unique molecular fingerprint of the tumor, not the tissue or organ from which the cancer originated. Patients entering clinical trials would be identified after comprehensive genomic and proteomic analysis and enrolled based on this molecular profile to maximize clinical outcome and minimize side effects. NantBioScience and NantWorks are uniquely positioned to develop molecularly designed drugs and identify patients and their tumor signature at the most granular levels with their suite of analytic tools and cloud based supercomputing capabilities. For more information please visit www.nantworks.com and follow Dr. Soon-Shiong on Twitter @solvehealthcare.
Contacts
NantWorks
Jen Hodson
562-397-3639
jhodson@nantworks.com
http://www.nantworks.com/
Dr. Patrick Soon-Shiong- Health 2.0 Conference
Silicon Valley
Santa Clara
Sept- 21st-24th,2014
http://www.health2con.com/events/speaker/patrick-soon-shiong/
Worked all day today...WOW 56 Posts on a Sunday. Have to do a lot of catching tonight. Things are heating up here!!!Hope SOON act SOON-ER than later. KEYO-BOOM!!BOOM!! Already.
Excellent DD from HMN2010,LESNSHAWN AND HESTERMAN on this board. Much appreciated by me and many others here!!!! Believers would wake up one morning with that "BOOM", Rocket-ship is about to liftoff!!! Zero time to get on board.!!!.
ipulator_man: Agreed.. Some one is trying to get our shares on the CHEAP!!! We, here on this this board have found a "GEM", a once of a lifetime opportunity, and I'm glad to be a part of it. I would to thank all the key players on this board for sharing their DD with supporting links and not "here say" information and hope they'll continue the journey all the way to the end, culminating with the fruits of their labor.
$$KEYO$$ would be a life changer!!!! GLTA on this board.
wilma6311:Obviously,you have no VESTED interest in KEYO stock. The investors here have done their DD on 'KeyOn Communications Holdings, Inc. (KEYO)' and weighed their risks-rewards in investing in KEYO stock. The KEYO stock holders here are prepared handle the outcome, regardless if it's a negative or positive. No one likes to lose their investment, but some of the greatest returns have come from investing in opportunities like 'KEYO. as you may well no there are no guarantees in any investment but calculated risks.
Dr.Soon-Soing has worked long, hard and meticulously with top scientists, doctors and even our president to promote his Healthcare plan on a global scale. It's my belief that this "Rocket-ship" is about to blast off into orbit sooner than later. Hope KEYO is the rocket fuel that would be utilized to propel this "ship" into the universe.
Sal, after viewing this video, I firmly believe some how, some way that KEYO is going to play a part in bring this "rocket-ship" to fruition.
Dr.Soon-Shoing Big health care plan:
For your viewing pleasure;
http://rolikionline.ru/watch/ZYkplV6U44M/dr-patrick-soon-shiong-confed2014.html
***ABSOLUTELY*** GO KEYO
This company's stock hit $195.00 earlier his year. Let's see what Nanthealth/KEYO could do in the near future.
Who would sell $325.00 worth of KEYO STOCK????? They definitely need the Money!!!
We have a quite a number of investors who have vested interest in KEYO, for us to take turns checking the DE SoS. Aframe and myself already did it.
LAST ANNUAL TAX 2014. TAX ASSESED 350.00
09.01.2011
aframe:Keyon Communications Holdings, Inc in Good Standing according to the DE SOS. Just paid and checked it.
Thanks JPGetty. I guess we just have to wait and see. HOLDING STRONG AND LONG
I'm a bit confused. If KEYO HOLDING (DE)is dissolved or will be dissolved, will KEYO HOLDING still be in play?
12.15 BST
Dr Patrick Soon-Shiong, a physician, medical researcher and businessman, says the healthcare system in the US is an "uncoordinated system of care".
He urges the UK not to fall into the mistake of electronic paper records which are merely "large filing cabinets".
He talks about cancer and outlines that by 2030, the number of cancer patients will have increased from 2 million to 4 million in the UK. He says the five-year survival rate is the lowest in all of Europe. Meanwhile in the US, 65% of pancreatic cancer patients got the wrong treatment from 2001-6. He asks: how are we going to address this?
www.theguardian.com/healthcare-network/2014/jun/05/jeremy-hunt-nhs-confederation-conference-today-in-healthcare-live#block-53904eb1e4b0301c656d401f
So what does this mean for KEYO shares aframe?? Is it still worthless